

This compilation of abstracts and presentations is for educational purposes only. Copies of abstracts and posters are for personal use only and may not be reproduced without permission from ASCO and the authors. Links to posters will not be accessible until presentation of the information at the ASCO congress.

Please note: *Abstract links will be available after May 19, 2021.*

Safety and Efficacy of AMG 160 Half-Life Extended BiTE[®] Immune Therapy Targeting Prostate-Specific Membrane Antigen (PSMA) in Combination With Other Agents for Earlier Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Presenter: Tobias Eggert

Day, Month Day, Year, Start Time – End Time Time Zone

Overall survival and exploratory subgroup analyses from the phase 2 CodeBreak 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer

Presenter: Benjamin Besse

Day, Month Day, Year, Start Time – End Time Time Zone

Patient-reported outcomes (PRO) from the phase 2 CodeBreak 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC)

Presenter: Jhanelle Gray

Day, Month Day, Year, Start Time – End Time Time Zone

Mutational Landscape with a Focus on KRAS Mutations in Non-Small Lung Cancer in Taiwan

Presenter: Stephen Gruber

Day, Month Day, Year, Start Time – End Time Time Zone

Feasibility of RECIST-based Real-world Tumor Response in Metastatic Non-small Cell Lung Cancer Patients

Presenter: Monika Izano

Day, Month Day, Year, Start Time – End Time Time Zone

Pathology Molecular Reflex Testing Improves TAT and Overall Molecular Testing Rates in NSCLC

Presenter: David R. Braxton

Day, Month Day, Year, Start Time – End Time Time Zone

Trial in progress: A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors

Presenter: Erika Hamilton

Day, Month Day, Year, Start Time – End Time Time Zone

Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC)

Presenter: Taofeek Owonikoko

Day, Month Day, Year, Start Time – End Time Time Zone

Trial-in-progress: A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer

Presenter: Rahul Aggarwal

Day, Month Day, Year, Start Time – End Time Time Zone

FIGHT: A randomized, double-blind, placebo-controlled, phase 2 study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC)

Presenter: Daniel Catenacci

Day, Month Day, Year, Start Time – End Time Time Zone

Risk factors associated with skeletal-related events following denosumab cessation among patients with bone metastases from solid tumors: A real-world machine learning approach

Presenter: TBD

Day, Month Day, Year, Start Time – End Time Time Zone